Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Kratom Benefits Controversy Explored as Adverse Effects Continue

By Gerald M. Slutzky, PhD
Posted on 14 Dec 2016
A recent review article addressed the ongoing controversy regarding the possible medical benefits of the chemically active compounds in the leaves of the kratom tree.

Kratom (Mitragyna speciosa) is a plant indigenous to Southeast Asia. More...
Its leaves and the teas brewed from them have long been used by people in that region to stave off fatigue and to manage pain and opioid withdrawal. While various kratom extracts are currently sold in the United States as herbal supplements, poison control centers noted 660 reports of adverse reactions to kratom products between January 2010 and December 2015. In August 2016, the US Drug Enforcement Administration announced plans to classify kratom and its mitragynine constituents as Schedule I controlled substances, the same classification as marijuana, LSD, and heroin. This classification would prevent the vast majority of U.S.-based researchers from studying kratom extract products.

The kratom controversy was addressed in a review article written by Dr. Walter Prozialeck, chairman of the department of pharmacology at Midwestern University Chicago (IL, USA), which was published in the December 2016 issue of The Journal of the American Osteopathic Association.

The report stated that during the period when kratom was classified in the USA as a legal herbal product it had been used for the self-management of opioid withdrawal and pain. Despite increasing numbers of reports of adverse effects resulting from use of kratom products, recent studies have confirmed that kratom and its chemical constituents do have useful pharmacologic actions.

The report presented an overview of the pharmacologically active compounds in kratom, including mitragynine, 7-hydroxymitragynine, paynantheine, speciogynine, and 20 other substances. It also examined the extensive amount of anecdotal evidence and current scientific research, which suggest that kratom may be safer and less addictive than current treatments for pain and opioid withdrawal.

"Many important medications, including the breast cancer treatment tamoxifen, were developed from plant research," said Dr. Prozialeck. "There is no question kratom compounds have complex and potential useful pharmacologic activities and they produce chemically different actions from opioids. Kratom does not produce an intense euphoria and, even at very high doses, it does not depress respiration, which could make it safer for users."

Related Links:
Midwestern University Chicago


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.